Assignee profile:

HANMI PHARM CO., LTD.

City:

Gyeonggi-do

Country:

South Korea

Published Applications:

15

Last publication date:

2026-01-01

Patent Grants:

10

Last grant date:

2025-07-08

Top Inventors for applications by HANMI PHARM CO., LTD.

These are the the leading inventors for applications assigned to HANMI PHARM CO., LTD.:

Recent patent applications by HANMI PHARM CO., LTD.

HANMI PHARM CO., LTD. based in Gyeonggi-do, KR has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2026-01-01
US20260000733A1
Human necessities

NOVEL METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX

#2 | 2025-12-04
US20250367257A1
Human necessities

METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX

#3 | 2024-03-14
US20240082355A1
Human necessities

LIQUID FORMULATION OF PROTEIN AND METHODS OF PREPARING THE SAME

#4 | 2024-01-25
US20240024426A1
Human necessities

HYPOTENSIVE PHARMACEUTICAL COMPOSITION COMPRISING TRIPLE ACTIVATOR HAVING ACTIVITY FOR ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS

#5 | 2023-10-19 ✅ Patent 12,350,315 granted on 2025-07-08
US20230330184A1
Human necessities

METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX

#6 | 2023-08-31 ✅ Patent 12,318,430 granted on 2025-06-03
US20230270822A1
Human necessities

Methods of treating neutorpenia using G-CSF protein complex

#7 | 2022-12-01
US20220378790A1
Human necessities

PHARMACEUTICAL PREPARATION COMPRISING AN AMIDE DERIVATIVE INHIBITING THE GROWTH OF CANCER CELL AND A PHARMACEUTICAL PRODUCT CONTAINING THE SAME

#8 | 2022-01-27 ✅ Patent 12,018,060 granted on 2024-06-25
US20220025012A1
Chemistry; metallurgy

Glucagon derivatives

#9 | 2019-08-08 ✅ Patent 10,946,003 granted on 2021-03-16
US20190240209A1
Human necessities

Formulation having improved pH-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof

#10 | 2018-01-04 ✅ Patent 10,513,550 granted on 2019-12-24
US20180002395A1
Chemistry; metallurgy

Glucagon derivatives

#11 | 2017-11-30 ✅ Patent 9,931,406 granted on 2018-04-03
US20170340744A1
Human necessities

Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant

#12 | 2017-10-19 ✅ Patent 10,233,230 granted on 2019-03-19
US20170298117A1
Chemistry; metallurgy

Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease

#13 | 2017-04-13 ✅ Patent 10,253,082 granted on 2019-04-09
US20170101455A1
Chemistry; metallurgy

Long-acting insulin and use thereof

#14 | 2015-12-03 ✅ Patent 9,518,043 granted on 2016-12-13
US20150344458A1
Chemistry; metallurgy

Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yi)prop-2-en-1-one

#15 | 2014-04-24 ✅ Patent 9,731,022 granted on 2017-08-15
US20140112962A1
Human necessities

Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant

Also check out HANMI PHARM CO., LTD.'s (Gyeonggi-do, South Korea) applicant profile with 17 patent applications submitted.

AssigneeID:

102674 ⎘